CN111821400A - Mongolian medicine for treating coronary heart disease and preparation method thereof - Google Patents
Mongolian medicine for treating coronary heart disease and preparation method thereof Download PDFInfo
- Publication number
- CN111821400A CN111821400A CN201910326977.5A CN201910326977A CN111821400A CN 111821400 A CN111821400 A CN 111821400A CN 201910326977 A CN201910326977 A CN 201910326977A CN 111821400 A CN111821400 A CN 111821400A
- Authority
- CN
- China
- Prior art keywords
- volatile oil
- heart disease
- coronary heart
- filtrate
- concentrating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
- A61K36/835—Aquilaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Mongolian medicine for treating coronary heart disease and a preparation method thereof, wherein the prescription comprises the following components in parts by weight: 450g of salvia miltiorrhiza, 225g of agilawood, 140g of nutmeg, 140g of fructus choerospondiatis, 140g of sea buckthorn, 135g of long pepper, 98g of rosewood, 48g of sandalwood and 73g of kaempferia galanga. The experiment shows that the invention can obviously change the clinical symptoms of patients with coronary heart disease and angina pectoris, and the effective rate of the clinical symptoms reaches 95 percent.
Description
Technical Field
The invention belongs to the technical field of Mongolian traditional Chinese medicines, and particularly relates to a Mongolian medicine for treating coronary heart disease and a preparation method thereof.
Background
Coronary heart disease angina belongs to the category of Gastrodia gigas disease in Guizhou medical science, is one of heart diseases which are mainly characterized by sudden precordial angina and unfixed angina symptoms which can be radiated to the left upper arm to the left hand ring finger and the like, and can cause symptoms of short breath, chest distress, hypodynamia and the like in the attack period. This disease begins in the four medical classics, classified as He-Yi type heartburn and Qi-element type heartburn, and is described in terms of symptoms and treatment. The Mongolian medicine considers that the disease is caused by imbalance of balance of three internal organs (Heyi, Hiri and Ba Da gan), unsmooth blood circulation of Tugeqi (governing the movement of qi of the heart), indigestion of clear blood (body fluid) and stasis and stagnation of blood vessels for nourishing the heart, and further causes qi and blood disorders such as blood turbidity, blood collection and the like in the cardiovascular vessels. The blood stasis of the heart black pulse is caused by the capture of the ghei and the qisu in the physical labor process or after emotional agitation, cold or satiety, so that the blood circulation of the heart black pulse is not smooth, the heart is damaged by myocardial ischemia and sudden cardiac prickling pain occurs. This is the disturbance of heart qi and blood, which leads to pain. The drugs for treating the diseases are not many, such as Mongolian medicine of Judi-5, Mongolian medicine of Guangzao-17, Mongolian medicine of Guangzao Qiwei powder, Mongolian medicine of allergy, forehead, and the like.
At present, the treatment drugs for coronary heart disease can be divided into western medicine and Chinese medicine: the fat infiltration theory of the western medicine treatment task is one of the most important theories in the mechanism of the coronary heart disease, the inflammation is an initiating factor of atherosclerosis, the inflammation causes local neutrophil and monocyte infiltration of blood vessels, the lipid deposition is promoted, and early lesions such as atherosclerosis fatty streak and the like are caused. The treatment methods mostly adopt the treatments of nitrates, beta-receptor blockers, calcium antagonists, converting enzyme inhibitors (ACEI), lipid-regulating drugs, antithrombotic drugs, interventional therapy (PCI), Coronary Artery Bypass Graft (CABG), heart transplantation and the like. Although the chemical medicine has obvious curative effect in clinic, the toxic and side effects of the chemical medicine are the most common, such as abdominal pain and diarrhea, hypotension, syncope and phlebitis are the second, severe granulocytopenia and liver dysfunction are caused, and the recurrence rate after treatment is also high; according to the principle that the symptoms are treated when the traditional Chinese medicine is used for treating coronary heart disease and angina pectoris and the root is treated when the traditional Chinese medicine is used for treating the symptoms when the patient is urgent and the symptoms are treated when the patient is slow, a quick-acting pain-relieving preparation is mainly selected in the attack stage to relieve cardiodynia and quickly control the condition of the patient, and quick-acting heart-saving pills, coronary heart storax pills, musk heart-protecting pills and the like are common medicines. In addition, the traditional Chinese medicine treatment adopts a traditional medicated bath method, an umbilical therapy, acupuncture therapy, aerosol inhalation therapy and the like, and the traditional medicated bath method, the traditional acupuncture therapy, the traditional aerosol inhalation therapy and the like are often used as auxiliary treatment methods for angina pectoris of coronary heart disease. CN200910011685.9 provides a pharmaceutical dripping pill for treating coronary heart disease, which is prepared from radix Salviae Miltiorrhizae, fructus Piperis Longi, lignum Aquilariae Resinatum, and lignum Dalbergiae Odoriferae by extracting, concentrating, drying, pulverizing, and mixing. The invention provides a Mongolian medicine capsule for treating coronary heart disease, aiming at the current situation.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides a Mongolian medicine for treating coronary heart disease and a preparation method thereof, wherein the Mongolian medicine comprises the following steps:
the prescription composition and dosage of the invention patent are as follows:
450g of salvia miltiorrhiza, 225g of agilawood, 140g of nutmeg, 140g of fructus choerospondiatis, 140g of sea buckthorn, 135g of long pepper, 98g of rosewood, 48g of sandalwood and 73g of kaempferia galanga. The auxiliary materials are as follows: beta-cyclodextrin, microcrystalline cellulose, magnesium stearate and superfine silica gel powder.
The production process comprises the following steps:
(1) extracting Saviae Miltiorrhizae radix with 10 times of 90% ethanol under reflux for three times (each time for 1.5 hr), filtering the extractive solution, recovering ethanol from the filtrate, and concentrating to obtain fluid extract with relative density of 1.05 (measured at 40 deg.C);
(2) crushing sandalwood, dalbergia wood and santalum album into coarse powder, crushing nutmeg, adding 8 times of water, soaking for 2 hours, extracting under reflux for 8 hours to obtain volatile oil, and collecting the residues and the water extract for later use;
(3) adding 4g of beta-cyclodextrin-containing saturated aqueous solution into each milliliter of the volatile oil, and performing inclusion for 2 hours at the temperature of 60 ℃ to obtain a volatile oil inclusion compound for later use;
(4) reflux-extracting Saviae Miltiorrhizae radix residue and fructus Choerospondiatis, fructus Hippophae, lignum Aquilariae Resinatum, rhizoma Kaempferiae, and fructus Piperis Longi with 10 times of 60% ethanol under heating for 2 times, each for 2 hr, mixing extractive solutions, filtering, recovering ethanol from filtrate, and concentrating to obtain fluid extract with relative density of 1.05 (measured at 40 deg.C);
(5) mixing the above ten medicinal residues, adding 8 times of water, decocting for 2 times, each time for 2 hr, filtering decoction, mixing filtrate with volatile oil water extractive solution, concentrating to obtain fluid extract with relative density of 1.06 (measured at 40 deg.C), adding ethanol to make ethanol content reach 60%, standing for 24 hr for precipitation, collecting supernatant, recovering ethanol, and concentrating to obtain fluid extract with relative density of 1.05 (measured at 40 deg.C);
(6) mixing the above fluid extracts, spray drying, adding volatile oil clathrate and appropriate amount of adjuvants (microcrystalline cellulose 10%, magnesium stearate 1%, and silica gel micropowder 1%), mixing, and making into capsule.
Compared with the prior art, the invention has the following advantages and beneficial effects:
the formula of the product is based on a large amount of salvia miltiorrhiza, and a plurality of aromatic and heart-protecting medicinal materials are applied. Besides promoting blood circulation by removing blood stasis, improving collateral circulation of coronary artery, regulating qi-flowing, strengthening heart, relieving pain, tranquilizing mind, improving and protecting vascular endothelial function, and protecting heart. The injection applied by patients with coronary heart disease and angina pectoris takes effect more quickly in the attack stage, but needs to be taken for a long time in the remission stage, the product has small toxic and side effects, is safe and effective, and is suitable for the people suffering from the diseases. Meanwhile, the composition of the medicinal materials of the product and the modern pharmacological research thereof provide scientific theoretical basis for treating coronary heart disease and angina pectoris
Detailed Description
The following detailed description of the embodiments of the present invention is provided for the purpose of illustration and not limitation, and should not be construed as limiting the scope of the invention.
The prescription consists of ten Mongolian medicinal materials of salvia miltiorrhiza, sandalwood, rosewood, santalum album, nutmeg, fructus choerospondiatis, sea buckthorn, agilawood, long pepper and kaempferia galanga. The literature reports that the salvia miltiorrhiza contains tanshinone and salvianolic acid B, the sandalwood contains volatile oil santalol, the rosewood contains volatile oil, flavonoid compounds, the pterocarpus santalinus mainly contains pterocarpin, homopterocarpin and angora pterocarpin, and the nutmeg contains volatile oil, fatty acid, cane sugar and other components; the fructus Choerospondiatis contains flavone and gallic acid; fructus Hippophae mainly contains flavone and isoflavone compounds, lignum Aquilariae Resinatum contains volatile oil and acidic components, rhizoma Kaempferiae contains kaempferol, and fructus Piperis Longi contains volatile oil and piperine. The effective components of the above medicinal materials include alcohol soluble effective components tanshinone, flavone, isoflavone compound, alkaloid, chlorogenic acid and sterol compound, and water soluble effective components salvianolic acid B and polysaccharide. Also contains volatile oil. Therefore, the process of the invention adopts a comprehensive extraction process of steam distillation, alcohol extraction and water extraction. And each extraction process is optimized through orthogonal design.
Comparative example 1
Taking 9 parts of sample, precisely weighing 300g of salvia miltiorrhiza per part, performing the test according to the table 1, recovering ethanol after extraction is finished, concentrating, and fixing the volume to a volumetric flask of 1000ml to obtain 9 parts of extract sample. Shaking the sample solutions uniformly, taking 1ml of each sample solution, respectively placing in a triangular flask, evaporating to dryness, adding 50ml of methanol, refluxing for 1h, filtering, and fixing the volume for later use. Accurately weighing tanshinone II A2.04mg in a 10ml volumetric flask, accurately sucking 2ml, and diluting to 25ml with methanol for use. Filtering the above extracted 9 sample solutions with microporous membrane, discarding the primary filtrate, collecting the secondary filtrate, injecting 10 μ l sample into EP tube, using methanol/water at 75: 25 as mobile phase, gas pressure of 3.0kpa, detector temperature of 70 deg.C, and measuring tanshinone II A content, the results are shown in Table 2.
TABLE 1 Salvia miltiorrhiza alcohol extraction Process investigation factors and levels
TABLE 2 orthogonal experimental design sheet and experimental results
Combining the above results, the optimum process conditions for tanshinol are as follows: a. the3B3C3D3The medicine materials are added with 90 percent ethanol in an amount which is 10 times of that of the medicine materials each time, and the reflux extraction is carried out for 2.5 hours and 3 times.
Comparative example 2
9 parts of samples are taken, wherein 115g of agilawood, 72g of fructus choerospondiatis, 72g of sea buckthorn, 37g of kaempferia galanga and 69g of long pepper are precisely weighed, and the total weight is 365 g. The resulting mixture was placed in a 5000ml ground flask and the experiments were performed as described in Table 3. After extraction, ethanol is recovered, concentrated, and respectively metered into volumetric flasks of 1000ml and shaken up. Precisely measuring 10ml of each sample solution into an evaporating dish, evaporating to dryness, adding 10ml of methanol into residues, heating and extracting for 1h, filtering, washing filter residues with methanol, metering the volume of filtrate to a 25ml volumetric flask, and shaking up for later use. The test shows that the common euphorbia root chromone and the total flavone in the coronary heart disease and blood circulation promoting capsule have similar absorption peaks at 297nm, so 297nm is selected as the measurement wavelength, and the experimental results are shown in table 4.
TABLE 3 investigation factors and level of total flavone alcohol extraction process of coronary heart disease and blood circulation promoting capsule
TABLE 4L9(34) Orthogonal experimental design table and experimental results
The results show that: the influence rule of each factor is as follows: d is more than C and more than A is more than B, and the optimal process condition is A2B2C2D3Namely 60% ethanol solution, 8 times of liquid adding amount, extracting for 2h under reflux, and extracting for 3 times. The final process condition from the actual production is A2B2C2D2Namely 60% ethanol solution, the liquid adding amount is 10 times, the reflux extraction is carried out for 2 hours, and the extraction is carried out for 2 times.
Comparative example 3
Sampling 9 parts of samples, precisely weighing 24g of sandalwood, 49g of rosewood, 24g of sandalwood and 72g of nutmeg in each part, testing according to the conditions in the table 5, and determining the collection amount of volatile oil of each sample by using a volatile oil extractor, wherein the test results are shown in the table 6.
TABLE 5 investigation factors and level of volatile oil extraction process of coronary heart disease promoting blood circulation capsule
TABLE 6L9(34) Orthogonal experimental design table and experimental results
The results show that: and finally setting the volatile oil extraction process to be 8 times of the liquid adding amount according to the visual analysis result, soaking for 2 hours, and extracting for 8 hours.
Comparative example 4
In order to reduce the volatilization of the volatile oil in the storage period, beta-cyclodextrin is adopted for inclusion. Precisely absorbing 9 parts of volatile oil, each part of which is 10ml, clathrating the volatile oil by a saturated aqueous solution method according to the experimental conditions listed in the table 7, and standing the clathrate in a refrigerator for 24 hours. The inclusion compound is filtered, dried at 40 ℃ and then introduced into a formula, the actual weight/(beta-CD + oil input) of the inclusion compound is multiplied by 100%, and the yield of the inclusion compound is calculated, and the result is shown in Table 8.
TABLE 7 investigation factors and level of volatile oil inclusion process of coronary heart disease promoting and blood circulation promoting capsule
TABLE 8L9(34) Orthogonal experimental design table and experimental results
The results show that: according to the visual analysis result, the volatile oil inclusion process is finally defined as adding 4g of beta-cyclodextrin saturated solution into each ml of volatile oil to perform inclusion for 2 hours at the temperature of 60 ℃.
Comparative example 5
In order to ensure that the water-soluble effective components can be fully extracted, the water extraction process is optimized through orthogonal design. Sampling 9 parts of samples, precisely weighing 230g of salvia miltiorrhiza, 115g of agilawood, 72g of fructus choerospondiatis, 72g of sea buckthorn, 37g of kaempferia galanga, 69g of long pepper, 24g of sandalwood, 49g of rosewood, 24g of sandalwood and 72g of nutmeg in each part, placing the mixture into a 10000ml ground flask, and arranging experiments according to an orthogonal design table in a table 9. After extraction, the mixture is concentrated under reduced pressure, and the concentrated solution is respectively added into volumetric flasks with the volume of 1000ml and shaken up. Drying 1ml of each solution in a triangular flask by distillation, adding 50ml of methanol, refluxing for 1h, filtering, and fixing the volume for later use. The results are shown in Table 10.
TABLE 9 investigation factors and level of water extraction process of radix Salviae Miltiorrhizae Capsule for coronary heart disease and promoting blood circulation
TABLE 10 orthogonal experimental design sheet and experimental results
The results show that: according to the water extraction process of the visual analysis result, the medicinal materials are finally decocted by adding 8 times of water for 2 hours each time.
Example 1
Preparation process
Prescription: 450g of salvia miltiorrhiza, 225g of agilawood, 140g of nutmeg, 140g of fructus choerospondiatis, 140g of sea buckthorn, 135g of long pepper, 98g of rosewood, 48g of sandalwood and 73g of kaempferia galanga. The auxiliary materials are as follows: beta-cyclodextrin, microcrystalline cellulose, magnesium stearate and superfine silica gel powder. The production prescription is amplified by 10 times on the basis of the original prescription.
The specific production process comprises the following steps:
adding 8 times of water into the sandalwood, the rosewood heart wood, the santalum album and the nutmeg, soaking for 2 hours, extracting for 8 hours under reflux to obtain volatile oil, and reserving dregs and water extract for later use; adding 4g of beta-cyclodextrin-containing saturated aqueous solution into each milliliter of volatile oil, and performing inclusion for 2 hours at the temperature of 60 ℃ to obtain a volatile oil inclusion compound for later use. Extracting Saviae Miltiorrhizae radix with 10 times of 90% ethanol under reflux for three times (each time for 1.5 hr), filtering the extractive solution, recovering ethanol from the filtrate, and concentrating to obtain fluid extract with relative density of 1.05 (measured at 40 deg.C); reflux-extracting Saviae Miltiorrhizae radix residue with fructus Choerospondiatis, fructus Hippophae, lignum Aquilariae Resinatum, rhizoma Kaempferiae, and fructus Piperis Longi with 10 times of 60% ethanol under heating for 2 times, each for 2 hr, mixing extractive solutions, filtering, recovering ethanol from filtrate, and concentrating to obtain fluid extract with relative density of 1.05 (measured at 40 deg.C). Mixing the above ten medicinal residues, adding 8 times of water, decocting for 2 times, each time for 2 hr, filtering decoction, mixing filtrate with volatile oil water extractive solution, concentrating to obtain fluid extract with relative density of 1.06 (measured at 40 deg.C), adding ethanol to make ethanol content reach 60%, standing for 24 hr for precipitation, collecting supernatant, recovering ethanol, and concentrating to obtain fluid extract with relative density of 1.05 (measured at 40 deg.C); mixing the above fluid extracts, spray drying, adding volatile oil clathrate and appropriate amount of adjuvants (microcrystalline cellulose 10%, magnesium stearate 1%, and silica gel micropowder 1%), mixing, and making into capsule 1 ten thousand.
Example 2
Test of drug efficacy
(1) Case selection: the 60 cases of the group all accord with chronic stable angina (II and III grade) which belongs to patients with qi deficiency and blood stasis syndrome by traditional Chinese medicine differentiation, the age is 40-60 years old, the average age is 50 years old, 38 cases of men and 22 cases of women. 30 cases of the medicinal preparation observation group and 30 cases of the Chinese medicinal granule for relieving sore throat and detoxifying are randomly selected.
(2) The observation method comprises the following steps: the taking method comprises the following steps: 3 granules/time, three times a day, and is taken after meals for one month continuously; the disease changes of the patient are observed periodically every week so as to treat the angina attack condition, the electrocardiogram change and the clinical symptoms (chest distress, chest pain, palpitation, shortness of breath, hypodynamia and the like) of the patient before and after treatment; according to the clinical observation table, the important vital signs of the patients before and after treatment, the exercise condition of the movable plate, the chief complaint, the blood pressure, the heart rate, the tongue condition, the pulse condition, the angina attack condition, the cardiac function and the like are observed and recorded at the follow-up time each time.
(3) Standard of therapeutic effect
The effect is shown: the main clinical symptoms disappear, and the symptoms of chest distress, chest pain, palpitation, short breath and hypodynamia are obviously improved;
the method has the following advantages: the clinical symptoms are relieved, and the symptoms of chest distress, chest pain, palpitation, short breath and hypodynamia are improved;
and (4) invalidation: the clinical symptoms are relieved or not relieved, and the symptoms of chest distress, chest pain, palpitation, short breath and hypodynamia are unchanged.
(4) Treatment outcome and efficacy analysis
The treatment results show that after the medicine is used for treating patients with symptoms of chest distress, chest pain, palpitation, shortness of breath and hypodynamia, the symptoms are obviously improved, 35 cases of obvious effect, 22 cases of effect and 3 cases of no effect are achieved, and the effective rate of clinical symptoms reaches 95%. Before and after treatment, heart rate, blood pressure, blood fat TC and TG have no obvious change. The patient has no obvious side effect during taking, has no adverse reaction of heart rate, blood sugar, liver function, kidney function and the like, and has no adverse reaction of headache, nausea, dizziness, sweating and the like. Therefore, the medicine has the functions of dilating coronary artery, increasing coronary blood flow, increasing myocardial oxygen deficiency, improving blood rheological property, reducing blood fat and the like, and can obviously change the clinical symptoms of patients with coronary heart disease and angina pectoris.
Claims (2)
1. A Mongolian medicine for treating coronary heart disease and a preparation method thereof are characterized in that the raw materials for preparing effective components are as follows:
2. the Mongolian medicine for treating coronary heart disease and the preparation method thereof, according to claim 1, is characterized in that: heating and refluxing salvia miltiorrhiza with ethanol to obtain filtrate, and concentrating the filtrate to obtain clear paste for later use; crushing sandalwood, dalbergia wood and santalum album into coarse powder, crushing nutmeg, extracting volatile oil with water under reflux, and collecting the residue and the water extract; ③ adding saturated aqueous solution of beta-cyclodextrin into the volatile oil to carry out inclusion to obtain volatile oil inclusion compound for later use; fourthly, adding ethanol into the salvia miltiorrhiza dregs, the fructus choerospondiatis, the sea buckthorn, the agilawood, the kaempferia galanga and the long pepper for heating and refluxing extraction to obtain an extracting solution, filtering to obtain a filtrate, and concentrating the filtrate to obtain a clear paste for later use; fifthly, mixing the above ten herb residues, adding water, decocting to obtain decoction filtrate, mixing with the volatile oil water extract, concentrating to obtain clear paste, adding ethanol, standing for 24 hours to precipitate, taking supernatant, and concentrating to obtain clear paste; sixthly, combining the clear paste, spray drying, adding the volatile oil inclusion compound and a proper amount of auxiliary materials, mixing uniformly, and encapsulating to obtain the capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910326977.5A CN111821400A (en) | 2019-04-16 | 2019-04-16 | Mongolian medicine for treating coronary heart disease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910326977.5A CN111821400A (en) | 2019-04-16 | 2019-04-16 | Mongolian medicine for treating coronary heart disease and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111821400A true CN111821400A (en) | 2020-10-27 |
Family
ID=72911432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910326977.5A Pending CN111821400A (en) | 2019-04-16 | 2019-04-16 | Mongolian medicine for treating coronary heart disease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111821400A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101554466A (en) * | 2009-05-19 | 2009-10-14 | 赤峰天奇制药有限责任公司 | Drug for treating coronary heart disease |
| CN108079235A (en) * | 2016-11-21 | 2018-05-29 | 内蒙古天奇中蒙制药股份有限公司 | A kind of capsule and its preparation process |
| CN108210810A (en) * | 2016-12-09 | 2018-06-29 | 内蒙古天奇中蒙制药股份有限公司 | A kind of preparation process of Chinese medicine composition |
-
2019
- 2019-04-16 CN CN201910326977.5A patent/CN111821400A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101554466A (en) * | 2009-05-19 | 2009-10-14 | 赤峰天奇制药有限责任公司 | Drug for treating coronary heart disease |
| CN108079235A (en) * | 2016-11-21 | 2018-05-29 | 内蒙古天奇中蒙制药股份有限公司 | A kind of capsule and its preparation process |
| CN108210810A (en) * | 2016-12-09 | 2018-06-29 | 内蒙古天奇中蒙制药股份有限公司 | A kind of preparation process of Chinese medicine composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105233246A (en) | Woodlouse small peptide drug for treating ischemic stroke | |
| CN101524469B (en) | Chinese herbal medicine compound preparation for treating congestive heart failure and preparation method thereof | |
| Wang et al. | Ethnopharmacological use, pharmacology, toxicology, phytochemistry, and progress in Chinese crude drug processing of the lateral root of Aconitum carmichaelii Debeaux.(Fuzi): a review | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| CN104666579A (en) | Traditional Chinese medicine composition for treating gonarthromeningitis and preparation method of traditional Chinese medicine composition | |
| CN104288245B (en) | Anti-aging and constitutional pharmaceutical composition and preparation method thereof and detection method | |
| CN109276685B (en) | The Chinese medicine composition and preparation method thereof of preventing/treating prostate class disease | |
| CN103933541B (en) | A kind of glutathion anti-cancer composition | |
| CN103100028A (en) | Soft capsule favorable for reducing alcoholic liver injury and preparation method thereof | |
| CN111821400A (en) | Mongolian medicine for treating coronary heart disease and preparation method thereof | |
| CN104645015A (en) | Traditional Chinese medicine compound preparation for treating vascular dementia and preparation method of traditional Chinese medicine compound preparation | |
| CN1132606C (en) | Medicine for curing coronary heart disease with hypertension and its preparation process | |
| CN105055967B (en) | A kind of complex health care product and preparation method with auxiliary hyperglycemic function | |
| CN107648335B (en) | Traditional Chinese medicine composition for regulating atherosclerosis autophagy and apoptosis and preparation method thereof | |
| CN108524576B (en) | Pharmaceutical composition for treating impotence, medicine and preparation method of medicine | |
| CN110522798A (en) | A kind of compound preparation and preparation method thereof curing mainly coronary heart disease | |
| CN106138494B (en) | Kidney nourishing composition and production method thereof | |
| CN103933216A (en) | Compound blood pressure lowering capsules for treating metabolic hypertension, preparation method and application thereof | |
| CN104547027B (en) | Preparation method and application of salvia miltiorrhiza leave and panax notoginseng leaf extract | |
| CN106309943A (en) | Coptis chinensis and kudzuvine root capsule and preparation method thereof | |
| CN103830426B (en) | One treats vasculitic Chinese medicine composition | |
| CN114767816B (en) | Traditional Chinese medicine composition for treating coronary heart disease and preparation method thereof | |
| CN107260816B (en) | A kind of pharmaceutical composition with antidepression effect and preparation method thereof | |
| CN105935439B (en) | Traditional Chinese medicine with effects of warming lung and descending turbidity and preparation method and application thereof | |
| CN107854651B (en) | Chinese medicinal preparation for treating apoplexy, hyperlipemia and blood hyperviscosity and production method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201027 |